Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0004-282x2011000200001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Harnessing Pharmacogenomics for Personalized Medicine: Tailoring Drug Therapy to Genetic Profiles.
Zhongguo Ying Yong Sheng Li Xue Za Zhi
December 2024
Maharaja Agrasen Himalayan Garhwal University, Pauri Garhwal, Uttarakhand, India, 246169.
This study means to investigate the capability of pharmacogenetics which can customize drug treatment through altered treatment of male genetic profiles. We finished hereditary profiling utilizing cutting edge sequencing (NGS) to figure out the key hereditary varieties that impact the medications metabolic adequacy and security. Patients were checked for a very long time to evaluate clinical results including ADRs and general wellness.
View Article and Find Full Text PDFPharmacists' Role in Pharmacogenomics: Transforming Promise to Reality Through Perseverance and Knowledge.
Sr Care Pharm
April 2024
Senior Partner, Geriatric Consultant Resources LLC Adjunct Associate Professor of Pharmacy The University of Michigan, Ann Arbor, Michigan.
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
Pharmacogenomics J
March 2024
CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
Article Synopsis
- Adverse drug reactions (ADRs) are a major public health issue, contributing to hospitalizations and being a leading cause of death, which also adds to healthcare costs globally.
- Genetic variations can affect how well certain drugs work and increase the likelihood of ADRs in patients taking commonly prescribed medications.
- Preemptive pharmacogenetic testing can enhance drug safety and efficacy by helping healthcare providers choose the right medications and dosages, ultimately reducing ADRs and improving patient care.
Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response?
Obes Pillars
March 2023
Department of Internal Medicine, University of Oklahoma, School of Community Medicine, 4502 E. 41st Street, Tulsa, OK, 74135, USA.
Background: Once thought to be primarily a result of lifestyle, it is now known that obesity has significant genetic components. Dozens of genes have been linked to obesity, and office-based genetic testing for obesity-associated genes is now readily available. As both pharmacotherapy and genetic testing for obesity become more accessible, pharmacogenetic personalization is becoming a reality.
View Article and Find Full Text PDFPharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?
Clin Transl Sci
July 2023
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Globally, tuberculosis (TB) is the second most lethal infectious disease. However, in sub-Saharan Africa, TB has the largest disease burden, with drug-resistant TB increasingly becoming a concern. The social and economic impact of TB should not be overlooked, especially in areas where healthcare systems are overburdened, and resources need to be allocated judiciously.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!